Introduction to the Theme “Precision Medicine and Prediction in Pharmacology”

Literature Cited

1. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ. 1.  et al. 2014. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:191998–2006 [Google Scholar]
2. Yan M, Parker BA, Schwab R, Kurzrock R. 2.  2014. HER2 aberrations in cancer: implications for therapy. Cancer Treat. Rev. 40:6770–80 [Google Scholar]
3. Stewart DJ, Kurzrock R. 3.  2013. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 13:193 [Google Scholar]
4. Vidyasagar M. 4.  2015. Identifying predictive features in drug response using machine learning: opportunities and challenges. Annu. Rev. Pharmacol. Toxicol. 55:15–34 [Google Scholar]
5. Kalgutkar AS, Dalvie D. 5.  2015. Predicting toxicities of reactive metabolite–positive drug candidates. Annu. Rev. Pharmacol. Toxicol. 55:35–54 [Google Scholar]
6. Cohen AF, Burggraaf J, van Gerven JMA, Moerland M, Groeneveld GJ. 6.  2015. The use of biomarkers in human pharmacology (Phase I) studies. Annu. Rev. Pharmacol. Toxicol. 55:55–74 [Google Scholar]
7. Hennessy S, Strom BL. 7.  2015. Improving postapproval drug safety surveillance: getting better information sooner. Annu. Rev. Pharmacol. Toxicol. 55:75–87 [Google Scholar]
8. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U. 8.  et al. 2015. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55:89–106 [Google Scholar]
9. Pui CH, Mullighan CG, Evans WE, Relling MV. 9.  2012. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there?. Blood 120:61165–74 [Google Scholar]
10. Relling MV. 10.  2012. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J. Pediatr. Pharmacol. Ther. 17:17–11 [Google Scholar]
11. Gross ER, Zambelli VO, Small BA, Ferreira JCB, Chen CH, Mochly-Rosen D. 11.  2015. A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant. Annu. Rev. Pharmacol. Toxicol. 55:107–27 [Google Scholar]
12. Park HW, Tantisira KG, Weiss ST. 12.  2015. Pharmacogenomics in asthma therapy: Where are we and where do we go. Annu. Rev. Pharmacol. Toxicol. 55:129–47 [Google Scholar]
13. Knibbe CAJ, Brill MJE, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. 13.  2015. Drug disposition in obesity: toward evidence-based dosing. Annu. Rev. Pharmacol. Toxicol. 55:149–67 [Google Scholar]
14. Naci H, Ioannidis JPA. 14.  2015. How good is “evidence” from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?. Annu. Rev. Pharmacol. Toxicol. 55:169–89 [Google Scholar]